Management of Resistant Hypertension

Initial Treatment Approach

The American College of Cardiology recommends adding a thiazide-like diuretic, such as chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 25-50 mg daily, as the third agent for a patient with uncontrolled hypertension, with chlorthalidone preferred due to its longer duration of action and superior outcomes in resistant hypertension 1
The American Heart Association suggests that clonidine is reserved as a last-line therapy due to significant CNS adverse effects, particularly in older adults, and risk of rebound hypertension with missed doses 1, 2

The American College of Cardiology recommends tapering clonidine gradually while adding a diuretic to avoid rebound hypertensive crisis, and never abruptly discontinuing clonidine 2
The American Heart Association suggests monitoring serum potassium and creatinine 2-4 weeks after initiation of a diuretic to detect hypokalemia or renal function changes 3
The American College of Cardiology recommends adding a calcium channel blocker, such as amlodipine 5-10 mg daily, once clonidine is discontinued, to complete the evidence-based triple therapy (ACE inhibitor + calcium channel blocker + thiazide diuretic) 1, 3

The American Heart Association suggests adding spironolactone 25-50 mg once daily as the preferred fourth-line agent for resistant hypertension, with the strongest evidence base, and monitoring potassium closely to avoid hyperkalemia 1, 4
The American College of Cardiology recommends considering beta-blocker therapy, such as metoprolol succinate 50-200 mg daily or bisoprolol 2.5-10 mg daily, only if heart rate ≥70 bpm or if compelling indications exist (coronary artery disease, heart failure, post-MI) 1, 2

The American Heart Association recommends reinforcing sodium restriction to <2 g/day (ideally <1.5 g/day) and promoting additional lifestyle modifications, such as weight loss, regular aerobic exercise, and a DASH dietary pattern, to achieve an additive 10-20 mmHg reduction in blood pressure 1, 3

The American College of Cardiology recommends targeting a blood pressure <130/80 mmHg for adults with a 10-year ASCVD risk ≥10%, and reassessing within 2-4 weeks after each medication adjustment to achieve target blood pressure within 3 months of treatment modification 5, 3, 4

The American Heart Association recommends replacing furosemide with chlorthalidone 12.5-25 mg daily for resistant hypertension, as thiazide-like diuretics are superior to loop diuretics unless the patient has significant chronic kidney disease (creatinine clearance <30 mL/min) 6
Chlorthalidone provides superior 24-hour blood pressure reduction compared to hydrochlorothiazide, with the largest difference occurring overnight 6
Loop diuretics like furosemide are short-acting and typically require twice-daily dosing, making them less effective for sustained blood pressure control 6

The American Journal of Kidney Diseases suggests that if the patient has stage G3a CKD, SGLT2 inhibitors can reduce the risk of serious hyperkalemia when used with RAAS inhibitors and mineralocorticoid receptor antagonists 7
Doxazosin (alpha-blocker) is an alternative fourth-line option with antihypertensive benefit beyond tamsulosin 7

Never use loop diuretics as first-line therapy for resistant hypertension unless creatinine clearance <30 mL/min 6